Exhibit 99.1
ASX, Nasdaq and Media Release
November 4, 2024
UPDATE -- Opthea to Participate in November Investor Conferences
Virtual Bell Potter Healthcare Conference, November 18, 2024
Jefferies London Healthcare Conference, November 19, 2024
Melbourne, Australia, and Princeton, NJ, US, November 4, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.
Conference details are as follows:
Bell Potter Healthcare Conference
Presentation: Monday, November 18, 2024, 3:00 PM AEDT (Virtual)
Presenter: Frederic Guerard, PharmD, CEO, Opthea
The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.
Jefferies London Healthcare Conference 2024
One-on-One Meetings: Tuesday, November 19, 2024
Participant: Frederic Guerard, PharmD, CEO, Opthea
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, Pharm D, CEO
| |
Investor Inquiries | Join our email database to receive program updates: |
PJ Kelleher LifeSci Advisors LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430 7579 Media Inquiries Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com | Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited |
